Predictive oncology has regained compliance with nasdaq's minimum bid price requirement

Minneapolis, feb. 02, 2021 (globe newswire) -- predictive oncology inc. (nasdaq: poai) (“predictive oncology” or “the company”), a knowledge-driven company focused on applying artificial intelligence (“ai”) to personalized medicine and drug discovery, today announced that based on a notification letter recently received from the listing qualifications department of the nasdaq stock market inc. (the “nasdaq”), the company has regained compliance with the minimum bid price requirement set forth in rule 5550(a)(2) of the nasdaq listing rules (the “minimum bid price requirement”).
POAI Ratings Summary
POAI Quant Ranking